Business
NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update
Over the past 12 months, the Company reinitiated its psychiatry development program post pandemic, transferred manufacturing of NRX-101 to the US, and
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"Over the past 12 months, the Company reinitiated its psychiatry development program post pandemic, transferred manufacturing of NRX-101 to the US, and initiated a clinical trial in suicidal treatment-resistant bipolar depression, which was recently reviewed by the independent Data Safety Monitoring Board (DSMB)The DSMB identified no safety or futility signals in the first 50 patients with Suicidal Treatment-Resistant Bipolar Depression enrolled in the trial; enrollment to continue as plannedThe current trial has been upgraded to a Phase 2b/3 study that may be used for a registrational filing; on track to report topline clinical data in 4Q 2023Initiated registrational Phase 3 clinical trial of NRX-101 in patients with bipolar depression with acute suicidal ideation and behavior (ASIB) and held Type B meeting with U.S. FDA in 1Q 2023, which provided important input to the NRX-101 programEnded 2022 with $20.1 million in cash and cash equivalents and announced subsequent $2.9 million registered direct offering in March 2023 to support pipeline of life-saving therapeutics.Two international leaders in Psychiatry, Prof. Andrew Nierenberg of Harvard Medical School and Prof. Marion Leboyer, of INSERM, Paris have joined the NRx Advisory BoardRADNOR, Pa., March 30, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\", the \"Company\"), a clinical-stage biopharmaceutical company, today announced its financial results for the full year 2022 and provided a business and clinical update.\nNRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update\"2022 was an exciting year of continued execution for NRx Pharmaceuticals as we reinitiated our psychiatry drug development program post-pandemic and advanced clinical development for our lead investigational compound, NRX-101, in Suicidal Treatment-Resistant Bipolar Depression,\" said Stephen Willard, J.D., Chief Executive Officer and Director of NRx Pharmaceuticals. \"We are delighted to augment our advisory board with two world-class leaders in psychiatry, Professors Andrew Nierenberg of Harvard Medical School, and Marion Leboyer of INSERM, one of France's leading universities. Prof. Nierenberg also serves as Principal Investigator of our ongoing Clinical Trials. The first few months of 2023 have been particularly productive. We initia...